Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04905277 · ClinicalTrials.gov registry record · Phase 2

Atenolol for the Prevention of Osteoporosis (APO)

A Phase 2 study of Healthy, sponsored by Sundeep Khosla, M.D..

Active
Registry status
Phase 2
Development phase
420
Enrollment target
3
Study locations

NCT04905277 is a Phase 2 study of Healthy that is active but no longer recruiting, run by Sundeep Khosla, M.D.. The registered enrollment target is 420 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (35% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04905277, a Phase 2 study of Healthy, is active but no longer recruiting, sponsored by Sundeep Khosla, M.D..

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
420 participants
Enrollment target
3
Study locations

Study Summary

Evaluate whether treatment with a widely used beta blocker, atenolol, will prevent bone loss at the lower back and hip in postmenopausal women.

Conditions Studied

Healthy

Interventions

  • DRUG Placebo
  • DRUG Atenolol 50 MG

Study Locations (3)

Maine

  • MaineHealth - Scarborough

Minnesota

  • Mayo Clinic - Rochester

New York

  • Columbia University Irving Medical Center - New York

Trial Details

FieldValue
Enrollment Target 420 participants
Start Date 2021-07-27
Est. Completion 2026-03-31
Phase Phase 2

Sponsor

Sundeep Khosla, M.D.

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04905277

The ClinicalTrials.gov registry entry for NCT04905277 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 420 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (35% lower). The listed sponsor is Sundeep Khosla, M.D., which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04905277 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Maine, Minnesota, New York.

Frequently Asked Questions

What is clinical trial NCT04905277 about?

NCT04905277 is a clinical study titled "Atenolol for the Prevention of Osteoporosis (APO)". Evaluate whether treatment with a widely used beta blocker, atenolol, will prevent bone loss at the lower back and hip in postmenopausal women.

What is the current status of trial NCT04905277?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 420 participants. The study started on 2021-07-27. Estimated completion is 2026-03-31.

What conditions does trial NCT04905277 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT04905277?

The interventions under investigation include: Placebo (DRUG), Atenolol 50 MG (DRUG).

Who is sponsoring clinical trial NCT04905277?

This trial is sponsored by Sundeep Khosla, M.D., which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04905277 being conducted?

This trial has 3 study locations across Maine, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Healthy

All registered trials for this condition

Maine

All trials with a study site in Maine

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.